Under the terms of the agreement, Galapagos’s service division BioFocus DPI will perform biology, medicinal chemistry and ADME/PK services for an Opsona drug discovery program. Opsona will make research payments to BioFocus DPI and fund the work of four to five BioFocus DPI scientists in 2009.
Onno van de Stolpe, CEO of Galapagos, said: “We are pleased to add Opsona Therapeutics, an emerging biotech with a promising pipeline and a successful follow-on financing round, to the growing list of BioFocus DPI customers.
“BioFocus DPI continues to attract top biotech, pharma and not-for-profit organizations as partners, resulting in one of the most well-rounded client bases in the business.”